The verdict
Our read at a glance.
Whether pasireotide's approved Cushing's disease and acromegaly uses are understood within those specific indications and their metabolic trade-offs, rather than generalized.
- The signal
- Randomized trials support pasireotide for lowering cortisol in Cushing's disease and growth hormone and IGF-1 in acromegaly. Across trials, high rates of hyperglycemia and new or worsened diabetes are a consistent finding.
- The unknown
- How to balance its hormone-lowering benefit against its strong tendency to raise blood sugar, and where it fits relative to surgery and other medical options.
- Our read
- A targeted option for serious hormone-excess conditions, defined as much by its glucose side effect as its benefit. Pasireotide works on the underlying hormone problem in Cushing's disease and acromegaly, but its strong tendency to raise blood sugar is central to using it.
The mechanism
How it works.
Pasireotide is a synthetic somatostatin analog that binds a wider range of somatostatin receptor subtypes than older drugs like octreotide, hitting SSTR5 strongly in addition to SSTR2. In Cushing's disease that broad binding shuts down ACTH release from pituitary tumor cells, which lowers cortisol, and in acromegaly it suppresses growth hormone. The same receptor profile suppresses insulin release from the pancreas, so it raises blood sugar more than other analogs.
Safety & regulatory boundary
The consequential part.
Pasireotide commonly causes hyperglycemia and can lead to new or worsened diabetes, and it also carries gallbladder, heart-rhythm (QT), and liver-related cautions. It is approved for specific endocrine indications, and the subcutaneous and long-acting products are not interchangeable. Approved products are not the same as compounded or research-labeled pasireotide, and the approved uses do not extend to general wellness claims.
What's next
What we're watching.
Long-term metabolic safety, comparative data against other Cushing's and acromegaly treatments, and strategies to manage its glucose effects.
Context
Why this is discussed.
Pasireotide is one of the few medical options for Cushing's disease that targets the underlying hormone excess, so it matters in a hard-to-treat condition.
The evidence base
22 cited references.
Regulatory & labels2
Recordati Rare Diseases, Inc. (FDA label) · 2026
Recordati Rare Diseases, Inc. (FDA label) · 2024
Registered trials8
ClinicalTrials.gov · PHASE3 · RECRUITING · 2025-05-30
ClinicalTrials.gov · PHASE2 · RECRUITING · 2024-02-27
ClinicalTrials.gov · PHASE1 · COMPLETED · 2025-12-01
ClinicalTrials.gov · PHASE3 · ACTIVE_NOT_RECRUITING · 2020-01-08
ClinicalTrials.gov · PHASE2 · COMPLETED · 2016-12-13
ClinicalTrials.gov · PHASE2 · ACTIVE_NOT_RECRUITING · 2024-01-04
ClinicalTrials.gov · RECRUITING · 2025-09-08
ClinicalTrials.gov · PHASE2 · TERMINATED · 2011-06
Indexed literature (PubMed)12
Colao A et al. · Nat Rev Dis Primers · 2019
Pivonello R et al. · Endocr Rev · 2015
Tack J et al. · Neurogastroenterol Motil · 2025
Molitch ME · JAMA · 2017
Gomes-Porras M et al. · Int J Mol Sci · 2020
PubMed · 2012
Zhang B et al. · Endocr Rev · 2025
Melmed S et al. · Nat Rev Endocrinol · 2025
Tilak M et al. · Indian J Cancer · 2023
Samson SL · Best Pract Res Clin Endocrinol Metab · 2026
van Beek AP et al. · Obes Rev · 2017
Valea A et al. · Exp Ther Med · 2022
Keep reading